University of Pittsburgh Cancer Institute-Hillman Cancer Center

Pittsburgh, Pennsylvania 15232

0 studies enrolling now · 15 studies all time

What they study most

Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Adenoid Cystic Carcinoma, Advanced Incurable Solid Malignancy, Breast Cancer, Carcinoma, Non Small Cell Lung, Head and Neck Squamous Cell Carcinoma (HNSCC), Hormone Refractory Prostate Cancer, Leukemia, Acute Myelogenous, Malignant Solid Tumour, Metastases to the Brain, Multiple Myeloma

Studies at this site

• PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
• Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases — Stopped early
• Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) — Stopped early
• Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia — Stopped early
• Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer — Completed
• Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA — Withdrawn before enrolling
• Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck — Completed
• Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome — Completed
• Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia — Stopped early
• Computed Tomography (CT) Perfusion Imaging of Lung Cancer — Stopped early
• Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies — Completed
• Study of GemOx and Vandetanib in Advanced Solid Malignancy — Completed
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — Completed
• Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma — Status unconfirmed
• ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body — Completed